DexCom, Inc. Stock (DXCM) - Quote Nasdaq- MarketScreener (2024)

Market Closed - Nasdaq Other stock markets 04:00:00 2024-08-21 pm EDT			5-day change	1st Jan Change
73.20 ^USD	+0.48%		+2.71%	-41.01%

Aug. 19	The Stock Market Olympics: Who's on the podium?
Aug. 16	RBC Adjusts DexCom's Price Target to $130 From $145, Keeps Outperform Rating	MT

Summary

Quotes

Charts

News

Company

Financials

Valuation

Consensus

Ratings

Calendar

Sector

ETFs

Valuation: DexCom, Inc.

(USD)

Capitalization	29.19B	P/E ratio 2024 *	43.9x	P/E ratio 2025 *	36.2x
Enterprise value	30.5B	EV / Sales 2024 *	7.6x	EV / Sales 2025 *	6.42x
Free-Float	97.79%	Yield 2024 *	-	Yield 2025 *	-

More valuation ratios * Estimated data

Chart: DexCom, Inc.

Duration

Period

Style

Latest news: DexCom, Inc.

The Stock Market Olympics: Who's on the podium?	Aug. 19
RBC Adjusts DexCom's Price Target to $130 From $145, Keeps Outperform Rating	Aug. 16	MT
DexCom's Glucose Monitoring System Available for Insurance Coverage in Quebec	Aug. 14	MT
Insulet inventory pressures cloud annual revenue forecast raise	Aug. 08	RE
Baird Adjusts Price Target on DexCom to $82 From $80	Aug. 05	MT
From Boom to Doom	Aug. 05
ANALYST RECOMMENDATIONS : Albemarle, Dexcom, Intel, Kellanova, Lloyds...	Aug. 05
Wall Street: a month-end boosted by the 'SOXX' with +6.7%.	Aug. 01	CF
Tech giants dish out the numbers amid Fed watch	Jul. 30
Redburn Atlantic Adjusts Price Target on DexCom to $80 From $130	Jul. 30	MT
ANALYST RECOMMENDATIONS : 3M Company, Aon, Murphy USA, Skyworks, Tesla...	Jul. 30
So far, global earnings are just good enough to feel disappointing	Jul. 30	RE
Tandem Diabetes Care, DexCom Say Health Canada Authorizes T:Slim X2 Insulin Pump	Jul. 29	MT

More news

Last Transcript: DexCom, Inc.

DexCom, Inc., Q2 2024 Earnings Call, Jul 25, 2024

Jul. 25

More transcripts

Analysts' recommendations: DexCom, Inc.

RBC Adjusts DexCom's Price Target to $130 From $145, Keeps Outperform Rating	Aug. 16	MT
Baird Adjusts Price Target on DexCom to $82 From $80	Aug. 05	MT
ANALYST RECOMMENDATIONS : Albemarle, Dexcom, Intel, Kellanova, Lloyds...	Aug. 05
Redburn Atlantic Adjusts Price Target on DexCom to $80 From $130	Jul. 30	MT
ANALYST RECOMMENDATIONS : 3M Company, Aon, Murphy USA, Skyworks, Tesla...	Jul. 30

More recommendations

Press Releases: DexCom, Inc.

	Aug. 21	PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of DexCom, Inc. - DXCM	Aug. 17	PR
	Aug. 14	PR
DXCM Investors Have Opportunity to Join DexCom, Inc. Securities Fraud Investigation with the Schall Law Firm	Aug. 12	PR
DXCM Investors Have Opportunity to Join DexCom, Inc. Securities Fraud Investigation with the Schall Law Firm	Aug. 12	PR

More press releases

News in other languages: DexCom, Inc.

Le Olimpiadi del mercato azionario: chi è sul podio?	Aug. 19
De Olympische Beursspelen: wie staat er op het podium?	Aug. 18
Die Börsenolympiade: Wer schafft es auf das Siegertreppchen?	Aug. 16
Las Olimpiadas bursátiles: ¿Quién sube al podio?	Aug. 16
La RAMQ élargit sa couverture provinciale pour inclure le Dexcom G7, offrant ainsi le système de SCG de nouvelle génération à un plus grand nombre de Québécois	Aug. 14

More news

Quotes and Performance

1 day	+0.48%
1 week	+2.71%
Current month	+7.93%
1 month	-34.44%
3 months	-43.99%
6 months	-37.90%
Current year	-41.01%

More quotes

Course Extremes

1 week

69.66

74.73

1 month

62.34

113.28

Current year

62.34

142.00

1 year

62.34

142.00

3 years

Managers and Directors: DexCom, Inc.

Director	Title	Age	Since
Kevin Sayer CEO	Chief Executive Officer	66	07-10-31
Jereme Sylvain DFI	Director of Finance/CFO	44	18-08-31
Shelly Selvaraj CTO	Chief Tech/Sci/R&D Officer	65	16-04-30

Manager	Title	Age	Since
Kevin Sayer CEO	Chief Executive Officer	66	07-10-31
Eric Topol BRD	Director/Board Member	69	09-07-08
Nick Augustinos BRD	Director/Board Member	65	09-11-19

More insiders

ETFs: DexCom, Inc.

Name	Weight	AuM	1st Jan change	Investor Rating
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	1.46%	14 M€	+10.87%	-
HAN-GINS INDXX HEALTHCARE MEGATREND EQUAL WEIGHT UCITS ETF - ACC - USD	1.04%	15 M€	-2.87%

More ETFs: DexCom, Inc.

Add to a list Add to a list 0 selected To use this feature you must be a member Log inSign up	Change	5d. change	1-year change	3-years change	Capi. ($)
DEXCOM, INC.	+0.48%	+2.71%	-30.07%	-42.08%	29.19B
ABBOTT LABORATORIES	+0.56%	+3.33%	+7.24%	-11.40%	193B
MEDTRONIC PLC	+2.53%	+7.82%	+7.27%	-32.10%	110B
BECTON, DICKINSON AND COMPANY	+0.05%	+0.31%	-14.79%	-5.26%	67.85B
HOYA CORPORATION	+1.04%	+0.13%	+26.26%	+18.71%	46.88B
CENCORA, INC.	+0.39%	+0.66%	+32.25%	+100.69%	46.73B
METTLER-TOLEDO INTERNATIONAL, INC.	+0.06%	+3.90%	+22.41%	-7.12%	30.36B
TERUMO CORPORATION	+3.24%	+1.51%	+34.01%	+22.67%	27.22B
STERIS PLC	+0.48%	+0.19%	+5.22%	+9.07%	23B
ZIMMER BIOMET HOLDINGS, INC.	+0.44%	+4.79%	-6.83%	-22.20%	22.74B
Average	+0.93%	+1.24%	+8.30%	+3.10%	59.62B
Weighted average by Cap.	+0.97%	+1.71%	+7.75%	-2.70%

See all sector performances

Financials

(USD)

	2024 *	2025 *
Net sales	4.01B	4.65B
Net income	670M	813M
Net Debt	1.3B	701M

More financial data * Estimated data

Company Profile

DexCom, Inc. specializes in the design, manufacture and marketing of continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers. The company provides an implantable device for continuous measurement of blood glucose levels and an external transmitter to which the sensor transmits glucose levels at specified intervals.The United States accounts for 72.5% of net sales.

Employees

9,550

Sector

Calendar

2024-10-23 - Q3 2024 Earnings Release (Projected)

Related indices

More about the company

Quotes

Date	Price	Change	Volume
24-08-21	73.20 $	+0.48%	4,150,587
24-08-20	72.85 $	-6.23%	7,704,715
24-08-19	77.69 $	+4.07%	3,645,990
24-08-16	74.65 $	+3.16%	3,122,863
24-08-15	72.36 $	+3.30%	4,827,378

Delayed Quote Nasdaq, August 21, 2024 at 04:00 pm EDT

More quotes

Income Statement and Estimates

More financial data

Analysis / Opinion

Dexcom: the bloodbath July 26, 2024 at 05:20 am EDT

More Strategies

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

72.85USD

Average target price

97.80USD

Spread / Average Target

+34.25%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Stock Market
Equities
DXCM Stock

Our Free Content Help you Secure and Increase the Performance of Your Investments Secure my Investments

"); for (var element in ICConf) { if (document.getElementById("zpp"+element)) { document.getElementById("zpp"+element).innerHTML = ""; } } InvestingChannelQueue.push(function() { ic_page = InvestingChannel.UAT.Run("5c5a75c3-8896-4592-98f8-dc06e6fdcc56"); }); } gaEvent('adspv', 'InvestingChannel_v2', 'US');googletag.cmd.push(function() { googletag.pubads().setTargeting('Edition', 'en_US');googletag.pubads().setTargeting('UserType', 'free');googletag.pubads().setTargeting('Content', 'equities');googletag.pubads().setTargeting('codezb', '9115');googletag.enableServices();googletag.pubads().collapseEmptyDivs();try{googletag.pubads().getSlots().forEach(function(slot){if(slot.getSlotElementId().startsWith('zpp')){;}else{googletag.pubads().refresh([slot],{changeCorrelator: false});}})}catch(error){console.error(error)}});$(document).ready(function() { $( document).on('zbv_visible',function () {startAdsService();}); if (document[zbv_hidden]===false) { startAdsService(); } });

DexCom, Inc. Stock (DXCM) - Quote Nasdaq- MarketScreener (2024)

FAQs

Is DexCom a buy or sell today? ›

DexCom stock has received a consensus rating of buy. The average rating score is and is based on 39 buy ratings, 22 hold ratings, and 0 sell ratings.

What is the future forecast for DexCom stock? ›

Based on short-term price targets offered by 22 analysts, the average price target for DexCom comes to $95.73. The forecasts range from a low of $75.00 to a high of $130.00. The average price target represents an increase of 29.24% from the last closing price of $74.07.

Tell Me More ›

What is the target price of DexCom? ›

Stock Price Targets

High	$130.00
Median	$92.50
Low	$75.00
Average	$96.18
Current Price	$73.67

What is the failure rate of DexCom? ›

We have been experiencing an extremely high failure rate for dexcom g6 cgm sensors since switching from g5. The g6 system is significantly better than g5 in most ways when all is working, but the sensors are apt to fail at least 25% of the time or higher.

Discover More Details ›

What is the 20 percent rule for DexCom? ›

In clinical studies, the results from home glucose testing devices are considered accurate if they pass the 20 rule (also known as the %20/20 rule). If the lab result is greater than 5.5 mmol/L (100 mg/dL) the CGM value must be no more than 20% higher or lower¹.

View Details ›

Is DexCom a good stock to buy now? ›

Dexcom has a consensus rating of Moderate Buy which is based on 14 buy ratings, 5 hold ratings and 0 sell ratings. The average price target for Dexcom is $104.68. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.

View Details ›

Is DexCom an acquisition target? ›

This audio is auto-generated. Please let us know if you have feedback. UPDATE: May 31, 2022: Dexcom said on Tuesday that it isn't in “active discussions regarding a merger transaction at this time,” following a report that the company was looking to acquire Insulet.

Discover More ›

What is the target range for DexCom? ›

The following are recommended ranges from an international consensus: Target Range: 70-180 mg/dL.

Tell Me More ›

Why is DexCom going down? ›

Dexcom offers a suite of tools such as continuous glucose monitors, or CGMs, for patients that have been diagnosed with diabetes. On the earnings call, CEO Kevin Sayer attributed the challenges to a restructuring of the company's sales team, fewer new customers than expected and lower revenue per user.

Learn More ›

Did DexCom stock split? ›

DexCom stock (symbol: DXCM) underwent a total of 1 stock split. The stock split occurred on June 13th, 2022.

Keep Reading ›